Health Technology Assessment
Systematic evaluation of clinical and economic value of a health technology.
Definition
HTA bodies evaluate the clinical effectiveness, safety, and cost-effectiveness of medical technologies to inform coverage and pricing - NICE (UK), HAS (France), G-BA/IQWiG (Germany), CADTH (Canada), and the new EU Joint Clinical Assessment (JCA). HTA reviews usually look at clinical evidence against a comparator, cost-effectiveness and budget impact, and sometimes ethical and organizational issues. Processes differ by country: some focus on clinical benefit, others on cost per QALY. Early scientific advice from HTA bodies helps companies design trials that both regulators and payers accept.What this means in practice
Outside the U.S., HTA decisions often gate market access. EU JCA (effective 2025) creates a single clinical assessment across member states for high-risk devices and IVDs.Examples
- A manufacturer of a novel orthopedic implant conducts a post-market clinical study to gather real-world effectiveness and cost utility data specifically for submission to Germany's G-BA.
- A diagnostic company developing a new in vitro diagnostic (IVD) test includes health economic endpoints in its clinical trial design to satisfy anticipated requirements from national HTA agencies.
- Before launching a new surgical robot in Canada, a MedTech company engages with CADTH to understand their evidence expectations for demonstrating value and securing reimbursement.
- •Misunderstanding HTA as a regulatory approval process, rather than a reimbursement and market access gate.
- •Failing to consider HTA requirements early in product development, leading to late-stage data collection challenges.
- •Underestimating the data requirements for HTA submissions, which often go beyond basic regulatory clinical evidence.
- •Assuming that a device approved in one jurisdiction will automatically receive favorable HTA outcomes in others.
- •Neglecting to engage with HTA bodies or experts during the clinical development planning phase.
Frequently asked questions
Cross-references
See also
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsReimbursement & Market Access
· From this learning pathFinancial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Payer requirement for approval before a service or device is covered.
AMA-maintained codes that describe medical procedures and services.
AMA-maintained codes used to report medical procedures and services for billing.
Where this term appears across MedTech Terms.
- Reimbursement & Market AccessLesson 11 of 14
Sources
2 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Official citation replacements checked: . Medicare documents support Medicare coding, coverage or payment context, not every payer policy or CPT editorial procedure. Citation replacement does not change the full term review date.
Inline markers like [1] jump to the matching reference above.